Important safety information for Compounded Tirzepatide



This page provides safety information for tirzepatide-based therapy. It is educational and does not replace your prescription label, your pharmacy's information, or your clinician's instructions. Always read the materials supplied with your medication.
Compounded tirzepatide is not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before they are marketed. A compounded medication is prepared by a pharmacy for an individual patient need based on a prescription from a licensed prescriber.
If you are prescribed a compounded formulation, your clinician should explain the reason and you should understand that its regulatory status differs from that of an FDA-approved product.
Tirzepatide-based therapy may be used in clinician-guided programs for chronic weight management in appropriate patients, alongside changes to nutrition and physical activity. Only a licensed clinician can determine whether it is appropriate for you.
Tirzepatide is not appropriate for everyone. It should not be used by people with a personal or family history of medullary thyroid carcinoma, people with Multiple Endocrine Neoplasia syndrome type 2, or anyone with a known hypersensitivity to tirzepatide or any component of the formulation. It is not used during pregnancy or while breastfeeding.
Careful evaluation is needed for people with a history of pancreatitis, gallbladder disease, significant kidney impairment, certain gastrointestinal conditions including gastroparesis, diabetic retinopathy, or a history of an eating disorder.
Tirzepatide belongs to a class carrying a boxed warning regarding thyroid C-cell tumors based on animal studies. Discuss this with your clinician.
Disclose all medications and supplements you take, including any past adverse reactions to medication.
Particular care is needed with insulin or sulfonylureas, since combining them with tirzepatide increases the risk of low blood sugar and may require adjustment of those medications. Because tirzepatide slows gastric emptying, it can also affect the absorption of oral medications, which is relevant for oral contraceptives and any medication with a narrow therapeutic range.
Do not combine tirzepatide with another GLP-1 or GLP-1/GIP medication unless a clinician has specifically directed it.
Seek medical care promptly for severe or persistent vomiting, an inability to keep fluids down, or signs of dehydration such as dizziness, very dark urine, or reduced urination; severe or persistent abdominal pain, especially pain radiating to the back, which can indicate pancreatitis; pain in the upper right abdomen, fever, or yellowing of the skin or eyes, which can indicate a gallbladder problem; signs of an allergic reaction such as rash, itching, swelling of the face or throat, or difficulty breathing; or new visual changes.
A new neck lump, persistent hoarseness, difficulty swallowing, or shortness of breath should be evaluated promptly.
For a severe reaction, difficulty breathing, or any symptom that feels like an emergency, call emergency services rather than waiting to reach your care team.
If your medication is supplied in a vial and you measure doses yourself, measurement error is a recognized risk. Syringe units measure volume, not milligrams, and the relationship between them depends on the concentration of your specific vial.
Your prescription and pharmacy label should state your dose in milligrams alongside the corresponding syringe units. If that mapping is not clear, do not estimate and do not inject. Contact your clinician or pharmacy first.
If you miss a dose, do not double up to compensate. Contact your care team for instructions. Never adjust your own dose.
Contact your care team with any question about side effects, measurement, or missed doses. When in doubt, ask before injecting.
Explore Luvo's Weight Loss Program.